![Robert C. Seid](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert C. Seid
Corporate Officer/Principal bij IOMAI CORPORATION
Profiel
Robert C.
Seid has been Vice President of Formulations for Iomai Corp.
since August 2005.
Prior to joining Iomai, he was Senior Director of Formulations and Process Development for Wyeth Wyeth Research and Director of Formulation Development for Aviron, Inc. He had over 20 years of experience in directing formulation optimization and characterization of biological products.
Dr. Seid received a BS degree in Chemistry from the University of California, Berkeley and a PhD in Chemistry from Boston University.
Actieve functies van Robert C. Seid
Bedrijven | Functie | Begin |
---|---|---|
IOMAI CORPORATION | Corporate Officer/Principal | 01-08-2008 |
Eerdere bekende functies van Robert C. Seid
Bedrijven | Functie | Einde |
---|---|---|
MedImmune Vaccines, Inc.
![]() MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Corporate Officer/Principal | - |
Wyeth Research
![]() Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Corporate Officer/Principal | - |
Opleiding van Robert C. Seid
University of California, Berkeley | Undergraduate Degree |
Boston University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Intercell USA, Inc.
![]() Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Wyeth Research
![]() Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Commercial Services |
MedImmune Vaccines, Inc.
![]() MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Health Technology |